Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands

The use of gold in medicine has a long history. Recent clinical applications include anti-inflammatory agents for the treatment of rheumatoid arthritis (chrysotherapy), and is currently being developed as potential anticancer chemotherapeutics. Gold(III), being isoelectronic to platinum(II) as in ci...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in chemistry 2020-11, Vol.8, p.587207-587207
Main Authors: Tong, Ka-Chung, Hu, Di, Wan, Pui-Ki, Lok, Chun-Nam, Che, Chi-Ming
Format: Article
Language:English
Subjects:
anticancer
biomolecular target
Chemistry
formulation
gold(III)
N-heterocyclic carbene
porphyrin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of gold in medicine has a long history. Recent clinical applications include anti-inflammatory agents for the treatment of rheumatoid arthritis (chrysotherapy), and is currently being developed as potential anticancer chemotherapeutics. Gold(III), being isoelectronic to platinum(II) as in cisplatin, is of great interest but it is inherently unstable and redox-reactive under physiological conditions. Coordination ligands containing C and/or N donor atom(s) such as porphyrin, pincer-type cyclometalated and/or N-heterocyclic carbene (NHC) can be employed to stabilize gold(III) ion for the preparation of anticancer active compounds. In this review, we described our recent work on the anticancer properties of gold(III) compounds and the identification of molecular targets involved in the mechanisms of action. We also summarized the chemical formulation strategies that have been adopted for the delivery of cytotoxic gold compounds, and for ameliorating the in vivo toxicity.
ISSN:2296-2646
2296-2646
DOI:10.3389/fchem.2020.587207